agilon health, inc. (NYSE:AGL - Get Free Report) Director Karen Mcloughlin bought 25,000 shares of the business's stock in a transaction on Friday, December 13th. The stock was purchased at an average cost of $2.20 per share, with a total value of $55,000.00. Following the purchase, the director now owns 73,166 shares of the company's stock, valued at $160,965.20. This represents a 51.90 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
agilon health Price Performance
Shares of NYSE:AGL opened at $2.25 on Friday. The business has a 50-day simple moving average of $2.44 and a two-hundred day simple moving average of $4.40. agilon health, inc. has a fifty-two week low of $1.50 and a fifty-two week high of $13.76. The firm has a market cap of $927.04 million, a price-to-earnings ratio of -2.39 and a beta of 0.51. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.29 and a current ratio of 1.29.
agilon health (NYSE:AGL - Get Free Report) last posted its earnings results on Thursday, November 7th. The company reported ($0.29) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.19). agilon health had a negative net margin of 6.88% and a negative return on equity of 47.84%. The firm had revenue of $1.45 billion during the quarter, compared to the consensus estimate of $1.47 billion. During the same period in the prior year, the company posted ($0.06) EPS. On average, analysts expect that agilon health, inc. will post -0.52 earnings per share for the current year.
Institutional Trading of agilon health
Why I'm telling friends to avoid gold stocks
From DTI | Ad
Back in November, gold made a tiny move of 1.6%.
But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week.
It happened again in March. Gold nudged up 1.2%.
This time? A 104% overnight gain.
And in June? A 1% gold move turned into a 74% gain in two weeks.
Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now.
There's a more lucrative way to play the gold market as we enter a new breakout period.
It's all about catching what I call "Acceleration Cycles."
And if you’d like to get your hands on this, here you go, the complete breakdown.
Hedge funds have recently bought and sold shares of the stock. Virtu Financial LLC purchased a new position in shares of agilon health in the third quarter valued at about $120,000. Geode Capital Management LLC grew its stake in shares of agilon health by 1.2% in the 3rd quarter. Geode Capital Management LLC now owns 6,893,517 shares of the company's stock worth $27,097,000 after buying an additional 84,889 shares in the last quarter. Barclays PLC increased its holdings in shares of agilon health by 21.2% in the 3rd quarter. Barclays PLC now owns 1,228,952 shares of the company's stock worth $4,830,000 after buying an additional 214,830 shares during the last quarter. XTX Topco Ltd raised its position in shares of agilon health by 271.1% during the 3rd quarter. XTX Topco Ltd now owns 119,747 shares of the company's stock valued at $471,000 after buying an additional 87,481 shares in the last quarter. Finally, State Street Corp lifted its holdings in shares of agilon health by 3.0% in the 3rd quarter. State Street Corp now owns 7,449,706 shares of the company's stock valued at $29,277,000 after acquiring an additional 215,733 shares during the last quarter.
Wall Street Analyst Weigh In
Several equities analysts recently commented on the stock. Evercore ISI reduced their target price on shares of agilon health from $7.00 to $4.00 and set an "in-line" rating on the stock in a report on Tuesday, October 8th. William Blair lowered agilon health from an "outperform" rating to a "market perform" rating in a research report on Friday, November 8th. Sanford C. Bernstein started coverage on agilon health in a research report on Wednesday. They issued a "market perform" rating and a $2.50 price objective for the company. Barclays dropped their price objective on agilon health from $5.00 to $2.00 and set an "underweight" rating for the company in a research note on Monday, November 11th. Finally, Citigroup lowered their price target on shares of agilon health from $2.50 to $1.75 and set a "sell" rating for the company in a report on Wednesday, November 13th. Three research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, agilon health presently has an average rating of "Hold" and a consensus target price of $4.38.
Check Out Our Latest Stock Analysis on agilon health
About agilon health
(
Get Free Report)
agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc and changed its name to agilon health, inc.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
